120 related articles for article (PubMed ID: 12582227)
21. Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar.
Sharma S; Sowjanya A; Kumari M; Suryaprakash R; Cynthia G; Suresh J; Chakrabarti R
Life Sci; 2006 Dec; 80(3):235-44. PubMed ID: 17014868
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
Liu K; Xu L; Berger JP; Macnaul KL; Zhou G; Doebber TW; Forrest MJ; Moller DE; Jones AB
J Med Chem; 2005 Apr; 48(7):2262-5. PubMed ID: 15801817
[TBL] [Abstract][Full Text] [Related]
23. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.
Dressel U; Allen TL; Pippal JB; Rohde PR; Lau P; Muscat GE
Mol Endocrinol; 2003 Dec; 17(12):2477-93. PubMed ID: 14525954
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
Nomura M; Tanase T; Ide T; Tsunoda M; Suzuki M; Uchiki H; Murakami K; Miyachi H
J Med Chem; 2003 Aug; 46(17):3581-99. PubMed ID: 12904063
[TBL] [Abstract][Full Text] [Related]
25. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.
Niho N; Takahashi M; Kitamura T; Shoji Y; Itoh M; Noda T; Sugimura T; Wakabayashi K
Cancer Res; 2003 Sep; 63(18):6090-5. PubMed ID: 14522940
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages.
Cabrero A; Cubero M; Llaverías G; Jové M; Planavila A; Alegret M; Sánchez R; Laguna JC; Carrera MV
Metabolism; 2003 May; 52(5):652-7. PubMed ID: 12759900
[TBL] [Abstract][Full Text] [Related]
27. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
Anandharajan R; Sayyed SG; Doshi LS; Dixit P; Chandak PG; Dixit AV; Brahma MK; Deshmukh NJ; Gupte R; Damre A; Suthar J; Padigaru M; Sharma SD; Nemmani KV
Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
[TBL] [Abstract][Full Text] [Related]
28. A water-soluble extract from Cucurbita moschata shows anti-obesity effects by controlling lipid metabolism in a high fat diet-induced obesity mouse model.
Choi H; Eo H; Park K; Jin M; Park EJ; Kim SH; Park JE; Kim S
Biochem Biophys Res Commun; 2007 Aug; 359(3):419-25. PubMed ID: 17548058
[TBL] [Abstract][Full Text] [Related]
29. Green tea (-)-epigallocatechin-3-gallate reduces body weight with regulation of multiple genes expression in adipose tissue of diet-induced obese mice.
Lee MS; Kim CT; Kim Y
Ann Nutr Metab; 2009; 54(2):151-7. PubMed ID: 19390166
[TBL] [Abstract][Full Text] [Related]
30. Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARbeta activity.
Sumanasekera WK; Tien ES; Davis JW; Turpey R; Perdew GH; Vanden Heuvel JP
Biochemistry; 2003 Sep; 42(36):10726-35. PubMed ID: 12962497
[TBL] [Abstract][Full Text] [Related]
31. Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)alpha activator, in non-human primates.
Schäfer SA; Hansen BC; Völkl A; Fahimi HD; Pill J
Biochem Pharmacol; 2004 Jul; 68(2):239-51. PubMed ID: 15193996
[TBL] [Abstract][Full Text] [Related]
32. PPARalpha governs glycerol metabolism.
Patsouris D; Mandard S; Voshol PJ; Escher P; Tan NS; Havekes LM; Koenig W; März W; Tafuri S; Wahli W; Müller M; Kersten S
J Clin Invest; 2004 Jul; 114(1):94-103. PubMed ID: 15232616
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.
Devasthale PV; Chen S; Jeon Y; Qu F; Shao C; Wang W; Zhang H; Cap M; Farrelly D; Golla R; Grover G; Harrity T; Ma Z; Moore L; Ren J; Seethala R; Cheng L; Sleph P; Sun W; Tieman A; Wetterau JR; Doweyko A; Chandrasena G; Chang SY; Humphreys WG; Sasseville VG; Biller SA; Ryono DE; Selan F; Hariharan N; Cheng PT
J Med Chem; 2005 Mar; 48(6):2248-50. PubMed ID: 15771468
[TBL] [Abstract][Full Text] [Related]
34. Changes in liver PPARalpha mRNA expression in response to two levels of high-safflower-oil diets correlate with changes in adiposity and serum leptin in rats and mice.
Hsu SC; Huang CJ
J Nutr Biochem; 2007 Feb; 18(2):86-96. PubMed ID: 16713235
[TBL] [Abstract][Full Text] [Related]
35. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.
Aasum E; Khalid AM; Gudbrandsen OA; How OJ; Berge RK; Larsen TS
J Mol Cell Cardiol; 2008 Jan; 44(1):201-9. PubMed ID: 17931655
[TBL] [Abstract][Full Text] [Related]
36. (2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.
Koyama H; Miller DJ; Boueres JK; Desai RC; Jones AB; Berger JP; MacNaul KL; Kelly LJ; Doebber TW; Wu MS; Zhou G; Wang PR; Ippolito MC; Chao YS; Agrawal AK; Franklin R; Heck JV; Wright SD; Moller DE; Sahoo SP
J Med Chem; 2004 Jun; 47(12):3255-63. PubMed ID: 15163205
[TBL] [Abstract][Full Text] [Related]
37. Effect of Chinese prescription Kangen-karyu on lipid metabolism in type 2 diabetic db/db mice.
Yamabe N; Kim HY; Kang KS; Zhao Q; Matsumoto K; Yokozawa T
J Ethnopharmacol; 2010 Jun; 129(3):299-305. PubMed ID: 20363309
[TBL] [Abstract][Full Text] [Related]
38. The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity.
Bełtowski J; Wójcicka G; Mydlarczyk M; Jamroz A
J Physiol Pharmacol; 2002 Sep; 53(3):463-75. PubMed ID: 12369742
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
Kurosaki E; Nakano R; Shimaya A; Yoshida S; Ida M; Suzuki T; Shibasaki M; Shikama H
Biochem Pharmacol; 2003 Mar; 65(5):795-805. PubMed ID: 12628477
[TBL] [Abstract][Full Text] [Related]
40. Anti-diabetic effect of amorphastilbol through PPARα/γ dual activation in db/db mice.
Lee W; Ham J; Kwon HC; Kim YK; Kim SN
Biochem Biophys Res Commun; 2013 Mar; 432(1):73-9. PubMed ID: 23376064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
